Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Mersana Therapeutics, Inc. (MRSN : NSDQ)

• Company Description    Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States. Number of Employees: 102

• Price / Volume Information    Yesterday's Closing Price: $0.36 Daily Weekly Monthly 20 Day Moving Average: 3,033,342 shares Shares Outstanding: 124.63 (millions) Market Capitalization: $45.28 (millions) Beta: 0.79 52 Week High: $2.83 52 Week Low: $0.26 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.02% -3.11% 12 Week 0.28% -12.66% Year To Date -74.59% -76.27%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 840 MEMORIAL DRIVE - CAMBRIDGE,MA 02139 USA ph: 617-498-0020 fax: - jason.fredette@mersana.com http://www.mersana.com

• General Corporate Information    Officers Martin Huber - Chief Executive Officer and President David Mott - Chairman of the Board Brian DeSchuytner - Chief Operating Officer and Senior Vice President Ashish Mandelia - Vice President and Chief Accounting Officer Lawrence M. Alleva - Director Peer Information Mersana Therapeutics, Inc. (CORR.) Mersana Therapeutics, Inc. (RSPI) Mersana Therapeutics, Inc. (CGXP) Mersana Therapeutics, Inc. (BGEN) Mersana Therapeutics, Inc. (GTBP) Mersana Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 59045L106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/12/25 Share - Related Items Shares Outstanding: 124.63 Most Recent Split Date: (:1) Beta: 0.79 Market Capitalization: $45.28 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.14 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.59 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 1.33 EPS Growth vs. Year Ago Period: -18.75% vs. Previous Quarter: -72.73% Sales Growth vs. Year Ago Period: -70.21% vs. Previous Quarter: -83.17% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - -990.16 ROA 06/30/25 - - 03/31/25 - -48.87 12/31/24 - -40.01 Current Ratio 06/30/25 - - 03/31/25 - 1.83 12/31/24 - 2.19 Quick Ratio 06/30/25 - - 03/31/25 - 1.83 12/31/24 - 2.19 Operating Margin 06/30/25 - - 03/31/25 - -217.63 12/31/24 - -170.86 Net Margin 06/30/25 - - 03/31/25 - -217.63 12/31/24 - -170.86 Pre-Tax Margin 06/30/25 - - 03/31/25 - -216.41 12/31/24 - -169.82 Book Value 06/30/25 - - 03/31/25 - -0.25 12/31/24 - -0.08 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©